ESTRO 2025 - Abstract Book

S1834

Clinical – Upper GI

ESTRO 2025

Results: The cohort included 41 patients, with a median age of 73.5 years and a median relapse-free interval of 10.2 months. Thirty six patients received pRT (20 Gy in 5 fractions or 30 Gy in 10 fractions), and 5 patients (11%) received cRT (50.4 Gy in 28 fractions with chemotherapy). Patient and treatment characteristics are shown in table 1.

The median cumulative dose was 56 Gy EQD2 10 . At the time of reirradiation, 16 patients (39%) had metastatic disease (M1). The median OS for non-metastatic (M0) patients treated with cRT, non-metastatic patients (M0) treated with pRT, and metastatic patients (M1) treated with pRT were 12.0, 9.8, and 2.8 months, respectively (p=0.003, figure 1).